MINA BARATIFAR: Open Payments
NPI 1922402189 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,414 in 100 payments from 26 companies in 2025. Trend: 2023 $2,667 · 2024 $2,044 · 2025 $2,414
Food & beverage: $2,414
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 5 | $264 |
| Eisai Inc. | 5 | $255 |
| UCB, Inc. | 9 | $236 |
| ABBVIE INC. | 13 | $231 |
| PFIZER INC. | 10 | $185 |
| Novartis Pharmaceuticals Corporation | 12 | $172 |
| ARGENX US, INC. | 5 | $171 |
| Merz Pharmaceuticals, LLC | 4 | $116 |
| Lilly USA, LLC | 5 | $102 |
| Vanda Pharmaceuticals Inc. | 3 | $76 |
Products named: AUSTEDO XR, Leqembi, KESIMPTA, VYVGART HYTRULO, NURTEC ODT, Xeomin, BOTOX, Fintepla.
Industry payments across TX — which companies pay providers there.
